ANI Pharmaceuticals Inc (ANIP) shareholders
Close on Nov 17, 2026Market cap $1.61BP/E 14.9Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 2,899,843 | 12.80% | 13G (passive) amendment | Jun 30, 2026 |
| Millennium Group Management LLC Joint filing with Millennium Management LLC (5.20%), Israel A. Englander (5.20%) and 1 more | 1,116,660 | 5.20% | 13G (passive) | May 30, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ANIP | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| BlackRock, Inc. | 2,958,646 | 12.88% | $244.92M | +211,154 | 0.00% |
| Soleus Capital Management, L.P. | 867,760 | 3.78% | $71.83M | +47,517 | 2.48% |
| Vanguard Capital Management LLC | 838,224 | 3.65% | $69.39M | +15,160 | 0.00% |
| State Street Corp | 831,647 | 3.62% | $68.86M | +60,060 | 0.00% |
| Tang Capital Management LLC | 707,500 | 3.08% | $58.57M | – | 2.66% |
| Dimensional Fund Advisors LP | 623,463 | 2.71% | $51.61M | +92,273 | 0.01% |
| American Century Companies Inc | 574,474 | 2.50% | $47.55M | +382,898 | 0.02% |
| Arrowstreet Capital, Limited Partnership | 562,016 | 2.45% | $46.52M | −2,344 | 0.02% |
| Global Alpha Capital Management Ltd. | 558,003 | 2.43% | $46.19M | +196,763 | 2.77% |
| Geode Capital Management, LLC | 536,407 | 2.34% | $44.41M | +47,206 | 0.00% |
| Millennium Management LLC | 507,207 | 2.21% | $41.99M | −84,806 | 0.02% |
| Nuveen, LLC | 415,024 | 1.81% | $34.36M | +12,667 | 0.01% |
| Vanguard Portfolio Management LLC | 407,281 | 1.77% | $33.71M | +31,316 | 0.00% |
| Ranger Investment Management, L.P. | 343,150 | 1.49% | $28.41M | −16,933 | 1.80% |
| Deutsche Bank AG\ | 323,443 | 1.41% | $26.77M | +3,768 | 0.01% |
| Invesco Ltd. | 309,233 | 1.35% | $25.60M | −15,116 | 0.00% |
| UBS Group AG | 297,539 | 1.30% | $24.63M | −200,163 | 0.00% |
| Kennedy Capital Management LLC | 295,938 | 1.29% | $24.50M | +1,942 | 0.43% |
| Ameriprise Financial Inc | 287,382 | 1.25% | $23.79M | +17,120 | 0.00% |
| Nomura Asset Management International Inc. | 287,206 | 1.25% | $23.78M | −357 | 0.04% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 307 | 23M | 100.0% | 53 / 120 | 89 / 24 | 3M | 3M |
| Q1 2026 | 281 | 23M | 100.0% | 45 / 111 | 83 / 45 | 6M | 3M |
| Q4 2025 | 285 | 21M | 92.2% | 49 / 113 | 79 / 31 | 4M | 3M |
| Q3 2025 | 269 | 21M | 89.5% | 62 / 82 | 85 / 24 | 5M | 4M |
| Q2 2025 | 232 | 20M | 86.9% | 28 / 88 | 77 / 25 | 3M | 3M |
| Q1 2025 | 230 | 20M | 87.2% | 48 / 63 | 75 / 20 | 3M | 2M |
| Q4 2024 | 205 | 19M | 84.1% | 31 / 69 | 60 / 31 | 3M | 3M |
| Q3 2024 | 208 | 19M | 84.8% | 39 / 87 | 43 / 30 | 8M | 2M |
| Q2 2024 | 201 | 15M | 66.7% | 33 / 73 | 63 / 30 | 2M | 2M |
| Q1 2024 | 200 | 15M | 64.6% | 41 / 65 | 53 / 22 | 2M | 1M |
| Q4 2023 | 182 | 14M | 61.3% | 31 / 55 | 53 / 34 | 2M | 2M |
| Q3 2023 | 186 | 13M | 57.5% | 30 / 73 | 51 / 16 | 2M | 1M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
294 funds held ANIP in Q2 2026, 54% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ANIP | Value | % of fund | As of |
|---|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 1,098,907 | 4.78% | $90.97M | 0.08% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 609,433 | 2.65% | $50.45M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 527,401 | 2.30% | $43.66M | 0.05% | Jun 30, 2026 |
| Avantis U.S. Small Cap Value ETF | 344,335 | 1.50% | $27.03M | 0.10% | May 31, 2026 |
| Oberweis Micro-Cap Fund | 256,300 | 1.12% | $21.22M | 1.31% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 224,189 | 0.98% | $17.76M | 0.05% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 209,103 | 0.91% | $17.31M | 0.02% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 204,469 | 0.89% | $16.93M | 0.01% | Jun 30, 2026 |
| Nomura Small Cap Growth Fund | 195,005 | 0.85% | $16.14M | 1.38% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 189,667 | 0.83% | $15.70M | 0.10% | Jun 30, 2026 |
| State Street(R) SPDR(R) Portfolio S&P 600(TM) Small Cap ETF | 166,958 | 0.73% | $13.82M | 0.08% | Jun 30, 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 163,598 | 0.71% | $13.54M | 0.16% | Jun 30, 2026 |
| Invesco Pharmaceuticals ETF | 151,712 | 0.66% | $12.02M | 2.55% | Jul 31, 2026 |
| abrdn U.S. Small Cap Equity Fund | 133,500 | 0.58% | $10.58M | 2.69% | Jul 31, 2026 |
| Invesco S&P SmallCap Momentum ETF | 122,617 | 0.53% | $9.72M | 0.32% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nikhil Lalwani | PRESIDENT & CEO, Director | 333,689 | 1.45% | Oct 16, 2026 |
| Muthusamy Shanmugam | HEAD OF R&D, COO-NOVITIUM OPS, Director | 537,976 | 2.34% | Mar 2, 2026 |
| Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | 72,924 | 0.32% | Nov 13, 2026 |
| Stephen P. Carey | SVP & CFO | 166,143 | 0.72% | Oct 30, 2026 |
| Ori Gutwerg | SVP, GENERICS | 75,534 | 0.33% | Aug 11, 2026 |
| Thomas Andrew Rowland | SVP, HEAD - ESTABLISHED BRANDS | 38,271 | 0.17% | May 13, 2026 |
| Christopher Mutz | HEAD OF RARE DISEASE | 91,309 | 0.40% | Mar 13, 2026 |
| Krista Davis | SVP, CHIEF HR OFFICER | 51,946 | 0.23% | Mar 10, 2026 |
| Chad Gassert | SVP - CORP. DEV. & STRATEGY | 233,406 | 1.02% | Mar 2, 2026 |
| Jeanne Thoma | Director | 26,762 | 0.12% | Sep 14, 2026 |
| Henry O. Gosebruch | Director | 6,662 | 0.03% | Aug 27, 2026 |
| Matthew J. Leonard | Director | 11,221 | 0.05% | Jun 10, 2026 |
| Thomas Haughey | Director | 38,878 | 0.17% | Jun 10, 2026 |
| Antonio R. Pera | Director | 27,017 | 0.12% | Jun 10, 2026 |
| Renee P. Tannenbaum | Director | 29,514 | 0.13% | Jun 10, 2026 |
| Patrick D. Walsh | Director | 38,432 | 0.17% | May 13, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Nov 13, 2026 | Sale(10b5-1 plan) | −500 | $70.80 | $35.40K | 72,924 |
| Stephen P. Carey SVP & CFO | Oct 29, 2026 | Sale(10b5-1 plan) | −2,850 | $72.87 | $207.68K | 166,143 |
| Nikhil Lalwani PRESIDENT & CEO, Director | Oct 15, 2026 | Sale(10b5-1 plan) | −5,400 | $71.89 | $388.21K | 333,689 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Oct 13, 2026 | Sale(10b5-1 plan) | −500 | $73.59 | $36.80K | 73,424 |
| Stephen P. Carey SVP & CFO | Sep 29, 2026 | Sale(10b5-1 plan) | −2,850 | $73.00 | $208.05K | 168,993 |
| Nikhil Lalwani PRESIDENT & CEO, Director | Sep 15, 2026 | Sale(10b5-1 plan) | −5,400 | $71.00 | $383.40K | 339,089 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Sep 14, 2026 | Sale(10b5-1 plan) | −500 | $70.79 | $35.40K | 73,924 |
| Jeanne Thoma Director | Sep 11, 2026 | Sale(10b5-1 plan) | −1,000 | $71.53 | $71.53K | 26,762 |
| Stephen P. Carey SVP & CFO | Aug 31, 2026 | Sale(10b5-1 plan) | −2,850 | $72.80 | $207.48K | 171,843 |
| Nikhil Lalwani PRESIDENT & CEO, Director | Aug 25, 2026 | Sale(10b5-1 plan) | −5,400 | $74.30 | $401.22K | 344,489 |
| Henry O. Gosebruch Director | Aug 19, 2026 | Award | +6,662 | – | – | 6,662 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Aug 13, 2026 | Sale(10b5-1 plan) | −500 | $75.48 | $37.74K | 74,424 |
| Ori Gutwerg SVP, GENERICS | Aug 10, 2026 | Sale | −3,162 | $77.00 | $243.47K | 75,534 |
| Stephen P. Carey SVP & CFO | Jul 29, 2026 | Sale(10b5-1 plan) | −2,850 | $81.36 | $231.88K | 174,693 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Jul 18, 2026 | Tax withholding | −2,466 | $79.20 | $195.31K | 74,924 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Jul 13, 2026 | Sale(10b5-1 plan) | −500 | $81.84 | $40.92K | 77,390 |
| Stephen P. Carey SVP & CFO | Jul 2, 2026 | Sale(10b5-1 plan) | −3,313 | $86.00 | $284.92K | 177,543 |
| Stephen P. Carey SVP & CFO | Jul 2, 2026 | Option exercise | +3,313 | $49.51 | $164.03K | 180,856 |
| Stephen P. Carey SVP & CFO | Jun 29, 2026 | Sale(10b5-1 plan) | −2,850 | $84.12 | $239.74K | 177,543 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Jun 12, 2026 | Sale(10b5-1 plan) | −500 | $82.03 | $41.02K | 77,890 |
| Thomas Haughey Director | Jun 8, 2026 | Sale(10b5-1 plan) | −2,000 | $80.88 | $161.76K | 38,878 |
| Stephen P. Carey SVP & CFO | Jun 5, 2026 | Option exercise | +3,312 | $49.51 | $163.98K | 183,705 |
| Stephen P. Carey SVP & CFO | Jun 5, 2026 | Sale(10b5-1 plan) | −3,312 | $80.00 | $264.96K | 180,393 |
| Antonio R. Pera Director | May 21, 2026 | Award | +4,357 | – | – | 27,017 |
| Thomas Haughey Director | May 21, 2026 | Award | +4,357 | – | – | 40,878 |
| Renee P. Tannenbaum Director | May 21, 2026 | Award | +4,357 | – | – | 29,514 |
| Matthew J. Leonard Director | May 21, 2026 | Award | +4,357 | – | – | 11,221 |
| Jeanne Thoma Director | May 21, 2026 | Award | +4,357 | – | – | 27,762 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | May 13, 2026 | Sale(10b5-1 plan) | −500 | $78.16 | $39.08K | 78,390 |
| Patrick D. Walsh Director | May 13, 2026 | Sale | −10,000 | $80.63 | $806.30K | 38,432 |
| Ori Gutwerg SVP, GENERICS | May 12, 2026 | Sale | −2,772 | $79.50 | $220.37K | 78,696 |
| Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | May 12, 2026 | Sale | −459 | $79.21 | $36.36K | 38,271 |
| Patrick D. Walsh Director | May 11, 2026 | Sale | −3,973 | $80.75 | $320.82K | 48,432 |
| Nikhil Lalwani PRESIDENT & CEO, Director | May 11, 2026 | Sale | −55,000 | $77.57 | $4.27M | 349,889 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Apr 13, 2026 | Sale(10b5-1 plan) | −500 | $77.95 | $38.98K | 78,890 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Mar 13, 2026 | Sale(10b5-1 plan) | −500 | $72.62 | $36.31K | 79,390 |
| Christopher Mutz HEAD OF RARE DISEASE | Mar 13, 2026 | Sale(10b5-1 plan) | −3,162 | $71.64 | $226.53K | 91,309 |
| Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | Mar 11, 2026 | Sale | −4,772 | $74.91 | $357.47K | 38,730 |
| Krista Davis SVP, CHIEF HR OFFICER | Mar 9, 2026 | Sale(10b5-1 plan) | −5,087 | $74.13 | $377.10K | 51,946 |
| Christopher Mutz HEAD OF RARE DISEASE | Mar 9, 2026 | Sale(10b5-1 plan) | −3,602 | $74.18 | $267.20K | 94,471 |
| Nikhil Lalwani PRESIDENT & CEO, Director | Mar 7, 2026 | Tax withholding | −17,060 | $74.04 | $1.26M | 404,889 |
| Ori Gutwerg SVP, GENERICS | Mar 7, 2026 | Tax withholding | −3,314 | $74.04 | $245.37K | 81,468 |
| Stephen P. Carey SVP & CFO | Mar 7, 2026 | Tax withholding | −5,150 | $74.04 | $381.31K | 180,393 |
| Christopher Mutz HEAD OF RARE DISEASE | Mar 7, 2026 | Tax withholding | −3,314 | $74.04 | $245.37K | 98,073 |
| Krista Davis SVP, CHIEF HR OFFICER | Mar 6, 2026 | Sale(10b5-1 plan) | −1,485 | $75.00 | $111.38K | 57,033 |
| Christopher Mutz HEAD OF RARE DISEASE | Mar 6, 2026 | Sale(10b5-1 plan) | −2,121 | $74.22 | $157.42K | 101,387 |
| Stephen P. Carey SVP & CFO | Mar 5, 2026 | Sale | −3,312 | $75.42 | $249.79K | 189,543 |
| Stephen P. Carey SVP & CFO | Mar 5, 2026 | Option exercise | +3,312 | $49.51 | $163.98K | 192,855 |
| Stephen P. Carey SVP & CFO | Mar 5, 2026 | Sale | −4,000 | $75.56 | $302.24K | 185,543 |
| Ori Gutwerg SVP, GENERICS | Mar 3, 2026 | Sale | −2,060 | $76.50 | $157.59K | 84,782 |
| Patrick D. Walsh Director | Mar 3, 2026 | Sale | −6,000 | $74.23 | $445.38K | 52,405 |
| Christopher Mutz HEAD OF RARE DISEASE | Mar 2, 2026 | Sale(10b5-1 plan) | −417 | $74.00 | $30.86K | 103,508 |
| Christopher Mutz HEAD OF RARE DISEASE | Feb 28, 2026 | Tax withholding | −2,221 | $73.90 | $164.13K | 103,925 |
| Nikhil Lalwani PRESIDENT & CEO, Director | Feb 28, 2026 | Tax withholding | −12,217 | $73.90 | $902.84K | 421,949 |
| Ori Gutwerg SVP, GENERICS | Feb 28, 2026 | Tax withholding | −2,221 | $73.90 | $164.13K | 86,842 |
| Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | Feb 28, 2026 | Tax withholding | −628 | $73.90 | $46.41K | 43,502 |
| Stephen P. Carey SVP & CFO | Feb 28, 2026 | Tax withholding | −2,773 | $73.90 | $204.92K | 189,543 |
| Krista Davis SVP, CHIEF HR OFFICER | Feb 28, 2026 | Tax withholding | −1,555 | $73.90 | $114.91K | 58,518 |
| Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | Feb 28, 2026 | Tax withholding | −1,555 | $73.90 | $114.91K | 79,890 |
| Chad Gassert SVP - CORP. DEV. & STRATEGY | Feb 28, 2026 | Tax withholding | −2,221 | $73.90 | $164.13K | 74,916 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ANI Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,188 shares on Aug 25, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Stephen P. Carey Officer | Oct 29, 2026 | 8,550 | $613.12K | Oct 29, 2026 | Restricted Stock Awards |
| Nikhil Lalwani Director, Officer | Oct 15, 2026 | 5,400 | $378.86K | Oct 15, 2026 | Restricted Stock Awards |
| Nikhil Lalwani Director, Officer | Sep 15, 2026 | 5,400 | $380.16K | Sep 15, 2026 | Restricted Stock Awards |
| Jeanne Thoma Director | Sep 11, 2026 | 1,000 | $71.46K | Sep 11, 2026 | Restricted Stock Awards |
| Nikhil Lalwani Director, Officer | Aug 25, 2026 | 5,400 | $400.52K | Aug 25, 2026 | RSA |
| Stephen P. Carey Officer | Jul 29, 2026 | 6,163 | $499.45K | Jul 29, 2026 | Restricted Stock Awards |
| Patrick D. Walsh Director | Jul 7, 2026 | 4,336 | $373.72K | Jul 7, 2026 | Restricted Stock |
| Thomas Haughey Director | Jun 8, 2026 | 2,000 | $162.22K | Jun 8, 2026 | Restricted Stock Awards |
| Stephen P. Carey Officer | Jun 5, 2026 | 11,862 | $939.47K | Jun 5, 2026 | Exercise of Stock Options |
| Patrick D. Walsh Director | May 13, 2026 | 10,000 | $795.60K | May 13, 2026 | Open Market Purchase |
| Patrick D. Walsh Director | May 11, 2026 | 3,973 | $320.82K | May 11, 2026 | Restricted Stock |
| Nikhil Lalwani Officer, Director | May 11, 2026 | 55,000 | $4.27M | May 11, 2026 | Performance Shares |
| Stephen P. Carey Officer | Mar 5, 2026 | 7,312 | $552.02K | Mar 5, 2026 | Restricted Stock |
| Patrick D. Walsh Director | Mar 3, 2026 | 6,000 | $445.39K | Mar 3, 2026 | Restricted Stock |
| Renate Plawner Tannenbaum 2024 Rv Trust Director | Dec 9, 2025 | 1,800 | $146.07K | Dec 5, 2025 | Restricted stock vesting under a registered plan |
See a number that looks wrong?